Joshua T. Baumgart
Salk Institute for Biological Studies(US)Torrey Pines Institute For Molecular Studies(US)
Publications by Year
Research Areas
Hippo pathway signaling and YAP/TAZ, PARP inhibition in cancer therapy, Cancer, Hypoxia, and Metabolism, Neuroblastoma Research and Treatments, Sarcoma Diagnosis and Treatment
Most-Cited Works
- → AMPK/ULK1-mediated phosphorylation of Parkin ACT domain mediates an early step in mitophagy(2021)152 cited
- → Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma(2019)128 cited
- → Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of AAV Serotypes 4, 5, and 11(2016)100 cited
- → HDAC3 is critical in tumor development and therapeutic resistance in Kras -mutant non–small cell lung cancer(2023)69 cited
- → Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma(2017)65 cited
- → Carcinogenesis and aging(1988)40 cited
- → STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma(2016)33 cited
- → Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma(2020)24 cited
- → The Role of PDGFR-β Activation in Acquired Resistance to IGF-1R Blockade in Preclinical Models of Rhabdomyosarcoma(2016)12 cited
- Influence of age on antileukemic action, subacute toxicity and tissue distribution of ambazone in B6D2F1 mice.(1990)